Organization type

  • Academic research institution
  • Service provider

Early phases

  • Biomarker identification
  • Omics
    • Genomics
    • Transcriptomics
  • Target identification – new biological hypothesis
  • Target validation – Hypothesis verification

Screening

  • Assay development
    • In vitro screening models
  • Chemical libraries
    • Natural product extracts: plants, microbial, animal (invertebrates, insects)
    • Small molecules (including natural product, DNA encoded libraries and fragment libraries)
  • Fragment based screening
    • Hit expansion. Medicinal chemistry programs.
  • Screening and high throughput screening using small molecules (including natural product, DNA encoded libraries and fragment libraries)

Optimization phases

  • In vitro biochemical models(including assay/model development and testing)
  • In vitro cellular and organotypic 3D models (including assay/model development and testing)
  • Mechanism of action (MoA) assessment
    • Functional cellular panels
    • Omics profiling
    • Selectivity panels
    • Target deconvolution
  • Preclinical phase (including assay/model development and testing)(non-regulatory and regulatory)
    • ADME / DMPK
    • Safety

Functional areas

  • Compound management
  • Molecular and cellular biology
    • Cell line generation
    • Flow cytometry
    • Imaging / High content screening
    • Mechanistic enzymology & receptorology
    • Microarrays
    • Protein expression / purification
    • qPCR
    • RNAseq
    • Sequencing

Terapeutic areas

  • Autoimmunity / Inflammation
  • Blood and lymphatic system
  • Cancer
  • Cardiovascular
  • Dermatology
  • Infectious diseases
  • Metabolism / Endocrinology
  • Nervous Central System
  • Ophthalmology / Optometry
  • Rare diseases

Additional activities

  • Consulting services
  • CROs providing no-regulatory and regulatory services for drug discovery